2026-04-13T06:50:35Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/59212025-10-24T10:38:10Zcom_2072_378070com_2072_378040col_2072_378092

Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity Younossi, Zobair M. Stepanova, Maria Esteban Mur, Rafael Jacobson, Ira Zeuzem, Stefan Sulkowski, Mark Institut Català de la Salut [Younossi ZM] Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA. Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA. [Stepanova M] Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA. Center for Outcomes Research in Liver Diseases (COR-LD), Washington, DC. [Esteban R] Servei de Medicina Interna, Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Jacobson I] Department of Medicine, Mount Sinai Medical Center, New York, NY. [Zeuzem S] Department of Internal Medicine, Goethe University Hospital, Frankfurt, Germany. [Sulkowski M] Department of Medicine, Johns Hopkins University, Baltimore, MD Vall d'Hebron Barcelona Hospital Campus Virus de l'hepatitis C Medicaments - Administració Pacients - Satisfacció DISEASES::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis C, Chronic Other subheadings::Other subheadings::Other subheadings::/drug therapy HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis crónica::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis C crónica Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida Antivirals d’acció directa; Fatiga; Productivitat laboral Antivirales de acción directa; Fatiga; Productividad laboral Direct-acting antivirals; Fatigue; Work productivity Patient-reported outcomes (PROs) such as quality of life and work productivity are important for measuring patient's experience. We assessed PROs during and after treatment of hepatitis C virus (HCV) patients. Data were obtained from a phase 3 open label study of sofosbuvir and ribavirin (SOF + RBV) with and without interferon (IFN). Patients completed 4 PRO assessment instruments (SF-36, Functional Assessment of Chronic Illness Therapy—Fatigue, Chronic Liver Disease Questionnaire— HCV, Work Productivity and Activity—Specific Health Problem) before, during, and after treatment. A total of 533 patients with chronic HCV were enrolled; 28.9% treatment-naïve, 23.1% cirrhotic, 219 received IFN + SOF + RBV and 314 received IFN-free SOF + RBV. At baseline, there were no differences in PROs between the IFN-free and IFN-containing treatment arms (all P > 0.05). During treatment, patients receiving IFN + SOF + RBV had a substantial impairment in their PROs (up to −24.4% by treatment week 12, up to −8.3% at week 4 post-treatment). The PRO decrements seen in the SOF + RBV arm were smaller in magnitude (up to −7.1% by treatment week 12), and all returned to baseline or improved by post-treatment week 4. By 12 weeks after treatment cessation, patients who achieved sustained viral response-12 showed some improvement of PRO scores regardless of the regimen (up to +7.1%, P < 0.0001) or previous treatment experience. In multivariate analysis, the use of IFN was independently associated with lower PROs. IFN-based regimens have a profoundly negative impact to PROs. By contrast, the impact of RBV on these PROs is relatively modest. Achieving HCV cure is associated with improvement of most of the PRO scores. 2021-04-28T10:48:35Z 2021-04-28T10:48:35Z 2017-02 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Younossi ZM, Stepanova M, Esteban R, Jacobson I, Zeuzem S, Sulkowski M, et al. Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity. Medicine (Baltimore). 2017 Feb;96(7):e5914.  1536-5964 https://hdl.handle.net/11351/5921 10.1097/MD.0000000000005914 28207507 000394432800011 http://hdl.handle.net/11351/5921 eng Medicine;96(7) https://journals.lww.com/md-journal/Fulltext/2017/02170/Superiority_of_Interferon_Free_Regimens_for.11.aspx Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Lippincott Williams & Wilkins Scientia